NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer
Authors
Shiu, K. K.Seligmann, J. F.
Graham, J.
Wilson, R. H.
Saunders, Mark P
Iveson, T.
Kayhanian, H.
Khan, K. H.
Rodriguez-Justo, M.
Jansen, M.
Obichere, A.
Plumb, A.
Seward, E.
Irvine, S.
Wilson, W.
Bhat, R.
Forsyth, S.
White, L.
Affiliation
University College Hospital, NHS Foundation Trust, LondonIssue Date
2022
Metadata
Show full item recordCitation
Shiu KK, Seligmann JF, Graham J, Wilson RH, Saunders MP, Iveson T, et al. NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680304912.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.TPS3645Type
Meetings and Proceedingsae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.TPS3645